

Clinical Oversight Review Board (CORB) Criteria for Prescribing/  
Criteria-Based Consultation (CBC) Criteria for Coverage  
**KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR  
COVERAGE**

## semaglutide (Wegovy oral)

**Notes:**

- Wegovy oral is covered under the prescription drug benefit for weight loss **ONLY for Kaiser Northwest members with coverage for medications used to treat weight loss**. Others pay member cash price.
- Contact Pharmacy Services in your home region to confirm your benefits for weight loss medications.
- Quantity Limits: Yes
- ^ Adequate trial is defined as a 3-month treatment duration
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- \*\*Does not apply to Medicare Part D patients

**Initiation (new start) criteria in adult patients for chronic weight management:** Non-formulary **semaglutide (Wegovy oral)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi-Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis for chronic weight management; **AND**
- Patient is 18 years of age or older; **AND**
- Patient's current weight and BMI has been documented within the last 30 days approximately; **AND**
- Patient is currently following a diet and exercise program; **AND**
- BMI greater than or equal to 30 kg/m<sup>2</sup> or BMI greater than or equal to 27 kg/m<sup>2</sup> AND has at least one of the following comorbid conditions documented:
  - Hypertension
  - Diabetes
  - Hyperlipidemia
- **-AND-**
- Patient has failed an adequate trial<sup>^</sup> to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - diethylpropion
  - topiramate
  - phentermine + topiramate or phentermine/topiramate (Qsymia)

kp.org

Revised: 01/08/26  
Effective: 03/19/26

All plans offered and underwritten by  
Kaiser Foundation Health Plan of the Northwest

Clinical Oversight Review Board (CORB) Criteria for Prescribing/  
Criteria-Based Consultation (CBC) Criteria for Coverage  
KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR  
COVERAGE

## semaglutide (Wegovy oral)

- naltrexone + bupropion or naltrexone/bupropion (Contrave)

**-AND-**

- Patient has then failed an adequate trial of semaglutide (Ozempic) followed by semaglutide (Wegovy injectable) unless patient has a documented needle phobia or is unable to safely inject due to visual impairment or physical disabilities (e.g. amputation, tremors/Parkinson's disease, rheumatoid arthritis)

**Initiation (new start) criteria in pediatric patients for obesity:** Non-formulary **semaglutide (Wegovy oral)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- No personal or family history of medullary thyroid carcinoma (MTC) or Multi-Endocrine Neoplasia syndrome type 2 (MEN 2)
- Diagnosis of class 2 or class 3 obesity; **AND**
- Patient is 12 to 17 years of age and is at least Tanner 2; **AND**
- Patient's current weight and BMI has been documented within the last 30 days approximately; **AND**
- Patient is currently following a diet and exercise program **AND**
- BMI greater than or equal to 35 kg/m<sup>2</sup> or at least 120% of 95<sup>th</sup> percentile

**-AND-**

- Patient has failed an adequate trial<sup>^</sup> to at least two of the following medications or medication combination therapies, or patient has an allergy, intolerance, or contraindication to all the following therapies:
  - phentermine
  - topiramate
  - phentermine + topiramate or phentermine/topiramate (Qsymia)

**-AND-**

- Patient has then failed an adequate trial of semaglutide (Ozempic) followed by semaglutide (Wegovy injectable) unless patient has a documented needle phobia or is unable to safely inject due to visual impairment or physical disabilities (e.g. amputation, tremors/Parkinson's disease, rheumatoid arthritis)

Clinical Oversight Review Board (CORB) Criteria for Prescribing/  
Criteria-Based Consultation (CBC) Criteria for Coverage  
**KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR  
COVERAGE**

## semaglutide (Wegovy oral)

**Initiation (new start) criteria for cardiovascular risk reduction/MACE:** Non-formulary **semaglutide (Wegovy oral)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- No personal or family history of medullary thyroid carcinoma (MTC) or Multi Endocrine Neoplasia syndrome type 2 (MEN 2)
- Patient does not have diabetes; **AND**
- BMI 27 or greater; **AND**
- Patient is currently following a diet and exercise program; **AND**
- Patient is 55 to 74 years of age; **AND**
- Patient has a history of STEMI or Type 1 NSTEMI; **AND**
- Occurrence of a STEMI or Type 1 NSTEMI while on semaglutide (Ozempic) 2 mg\*\*

**-AND-**

- Patient has then failed an adequate trial of semaglutide (Wegovy injectable) unless patient has a documented needle phobia or is unable to safely inject due to visual impairment or physical disabilities (e.g. amputation, tremors/Parkinson's disease, rheumatoid arthritis)

**Continued use criteria (every 12 months) for patients previously reviewed and approved when used for chronic weight management:** Non-formulary **semaglutide (Wegovy oral)** will continue to be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient's updated weight and BMI are recently documented; **AND**
- Achieved and maintained 5% or greater weight loss after starting semaglutide (Wegovy)

**Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously when used for weight loss:**

Non-formulary **semaglutide (Wegovy oral)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient has a prescription drug insurance benefit that covers medications used to lose weight; **AND**
- Patient is using for chronic weight management/obesity; **AND**

Clinical Oversight Review Board (CORB) Criteria for Prescribing/  
Criteria-Based Consultation (CBC) Criteria for Coverage  
KAISER PERMANENTE NORTHWEST REGION CRITERIA FOR  
COVERAGE

## semaglutide (Wegovy oral)

- Patient has failed an adequate trial of semaglutide (Ozempic) followed by semaglutide (Wegovy injectable) unless patient has a documented needle phobia or is unable to safely inject due to visual impairment or physical disabilities (e.g. amputation, tremors/Parkinson's disease, rheumatoid arthritis)

**Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously when used for cardiovascular risk reduction/MACE:** Non-formulary **semaglutide (Wegovy oral)** will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Patient is using for cardiovascular risk reduction/MACE; **AND**
- Patient has failed an adequate trial of semaglutide (Ozempic) followed by semaglutide (Wegovy injectable) unless patient has a documented needle phobia or is unable to safely inject due to visual impairment or physical disabilities (e.g. amputation, tremors/Parkinson's disease, rheumatoid arthritis)